IQV
IQVIA Holdings Inc. NYSE Listed May 9, 2013$178.71
Mkt Cap $30.3B
52w Low $134.65
39.2% of range
52w High $247.05
50d MA $169.41
200d MA $197.13
P/E (TTM)
19.9x
EV/EBITDA
15.3x
P/B
4.1x
Debt/Equity
2.5x
ROE
20.9%
P/FCF
18.9x
RSI (14)
—
ATR (14)
—
Beta
1.39
50d MA
$169.41
200d MA
$197.13
Avg Volume
2.1M
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
2400 Ellis Road · Durham, NC 27703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | 2.83 | 2.90 | +2.5% | 176.42 | +2.2% | +0.0% | +1.2% | — | — | — | — |
| Feb 5, 2026 | TNS | 3.40 | 3.42 | +0.6% | 180.96 | +1.2% | +3.6% | +0.0% | +2.8% | -5.3% | -2.9% | — |
| Oct 28, 2025 | TNS | 2.98 | 3.00 | +0.7% | 218.13 | +0.9% | -0.1% | +0.0% | -0.6% | -0.0% | -1.2% | — |
| Jul 22, 2025 | TNS | 2.77 | 2.81 | +1.4% | 187.38 | +2.1% | +3.7% | +0.0% | +3.4% | -0.8% | -0.7% | — |
| May 6, 2025 | TNS | 2.63 | 2.70 | +2.7% | 146.20 | +2.3% | +4.9% | +0.0% | -0.0% | -2.8% | +4.8% | — |
| Feb 6, 2025 | TNS | 3.11 | 3.12 | +0.3% | 209.96 | +0.8% | -0.9% | +0.0% | -0.6% | -2.9% | -1.5% | — |
| Oct 31, 2024 | TNS | 2.82 | 2.84 | +0.7% | 205.82 | +0.1% | +1.6% | +0.0% | +0.5% | +1.3% | +3.9% | — |
| Jul 22, 2024 | TNS | 2.56 | 2.64 | +3.1% | 245.23 | -1.3% | -2.6% | +0.0% | -0.0% | -2.7% | +3.2% | — |
| May 2, 2024 | TNS | 2.49 | 2.54 | +2.0% | 222.14 | +0.6% | +0.6% | +0.0% | +1.6% | +0.9% | -0.5% | — |
| Feb 14, 2024 | TNS | 2.82 | 2.84 | +0.7% | 243.47 | -0.6% | -0.8% | +0.0% | -1.2% | -1.6% | +1.1% | — |
| Nov 1, 2023 | TNS | 2.46 | 2.49 | +1.2% | 180.01 | +0.6% | +5.8% | +0.0% | +3.5% | +0.6% | +0.8% | — |
| Aug 1, 2023 | TNS | 2.37 | 2.43 | +2.5% | 219.13 | -1.0% | -0.0% | +0.0% | -1.3% | +0.3% | +1.1% | — |
| Apr 27, 2023 | BMO | 2.41 | 2.45 | +1.7% | 183.66 | -0.3% | +2.5% | +0.0% | +0.9% | -2.3% | +0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $170.62 | $175.39 | +2.8% | +1.1% | -2.1% | -1.0% | +2.8% | +1.9% |
| Mar 9 | TD Cowen | Upgrade | Hold → Buy | — | $174.49 | $174.49 | +0.0% | +2.3% | -4.3% | +0.4% | -5.0% | +1.1% |
| Mar 6 | Barclays | Upgrade | Equal Weight → Overweight | — | $178.50 | $178.20 | -0.2% | -2.2% | +2.3% | -4.3% | +0.4% | -5.0% |
| Feb 19 | Truist | Maintains | Buy → Buy | — | $171.06 | $169.05 | -1.2% | -1.0% | -2.2% | -2.0% | +1.6% | -1.8% |
| Feb 6 | Stifel | Maintains | Buy → Buy | — | $180.96 | $183.12 | +1.2% | +3.6% | +2.8% | -5.3% | -2.9% | -4.7% |
| Feb 6 | Citigroup | Maintains | Neutral → Neutral | — | $180.96 | $183.12 | +1.2% | +3.6% | +2.8% | -5.3% | -2.9% | -4.7% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $180.96 | $183.12 | +1.2% | +3.6% | +2.8% | -5.3% | -2.9% | -4.7% |
| Feb 6 | Jefferies | Maintains | Buy → Buy | — | $180.96 | $183.12 | +1.2% | +3.6% | +2.8% | -5.3% | -2.9% | -4.7% |
| Feb 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $180.96 | $183.12 | +1.2% | +3.6% | +2.8% | -5.3% | -2.9% | -4.7% |
| Feb 6 | UBS | Maintains | Buy → Buy | — | $180.96 | $183.12 | +1.2% | +3.6% | +2.8% | -5.3% | -2.9% | -4.7% |
| Jan 22 | TD Cowen | Maintains | Hold → Hold | — | $241.40 | $242.00 | +0.2% | -1.0% | -1.6% | +1.8% | +0.7% | -0.5% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $244.29 | $241.65 | -1.1% | -0.5% | -0.3% | -0.6% | +0.3% | -0.1% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $244.29 | $241.65 | -1.1% | -0.5% | -0.3% | -0.6% | +0.3% | -0.1% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $228.47 | $228.16 | -0.1% | -1.2% | +0.7% | -1.0% | +0.4% | -1.0% |
| Nov 3 | TD Cowen | Downgrade | Buy → Hold | — | $216.46 | $212.42 | -1.9% | -1.2% | -1.4% | -0.4% | +0.4% | -0.2% |
| Oct 29 | UBS | Maintains | Buy → Buy | — | $218.13 | $220.00 | +0.9% | -0.1% | -0.6% | -0.0% | -1.2% | -1.4% |
| Oct 29 | Stifel | Maintains | Buy → Buy | — | $218.13 | $220.00 | +0.9% | -0.1% | -0.6% | -0.0% | -1.2% | -1.4% |
| Oct 29 | Citigroup | Maintains | Neutral → Neutral | — | $218.13 | $220.00 | +0.9% | -0.1% | -0.6% | -0.0% | -1.2% | -1.4% |
| Oct 29 | Baird | Upgrade | Neutral → Outperform | — | $218.13 | $220.00 | +0.9% | -0.1% | -0.6% | -0.0% | -1.2% | -1.4% |
| Oct 29 | Truist | Maintains | Buy → Buy | — | $218.13 | $220.00 | +0.9% | -0.1% | -0.6% | -0.0% | -1.2% | -1.4% |
| Oct 29 | JP Morgan | Maintains | Overweight → Overweight | — | $218.13 | $220.00 | +0.9% | -0.1% | -0.6% | -0.0% | -1.2% | -1.4% |
| Oct 9 | HSBC | Upgrade | Hold → Buy | — | $200.60 | $203.09 | +1.2% | +1.2% | -2.4% | +2.8% | +0.5% | -0.8% |
| Oct 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $200.86 | $200.00 | -0.4% | -0.1% | +1.2% | -2.4% | +2.8% | +0.5% |
| Oct 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $203.79 | $202.71 | -0.5% | +0.3% | +1.1% | -0.8% | -2.0% | -0.1% |
| Sep 9 | Jefferies | Upgrade | Hold → Buy | — | $187.68 | $191.34 | +2.0% | +1.0% | -3.0% | +3.7% | -1.8% | -0.7% |
| Jul 25 | Mizuho | Maintains | Outperform → Outperform | — | $200.82 | $201.04 | +0.1% | -0.8% | -0.7% | -1.6% | -1.5% | -3.0% |
| Jul 23 | UBS | Maintains | Buy → Buy | — | $187.38 | $191.27 | +2.1% | +3.7% | +3.4% | -0.8% | -0.7% | -1.6% |
| Jul 23 | Truist | Maintains | Buy → Buy | — | $187.38 | $191.27 | +2.1% | +3.7% | +3.4% | -0.8% | -0.7% | -1.6% |
| Jul 23 | Citigroup | Maintains | Neutral → Neutral | — | $187.38 | $191.27 | +2.1% | +3.7% | +3.4% | -0.8% | -0.7% | -1.6% |
| Jul 23 | Barclays | Maintains | Equal Weight → Equal Weight | — | $187.38 | $191.27 | +2.1% | +3.7% | +3.4% | -0.8% | -0.7% | -1.6% |
| Jul 23 | Baird | Maintains | Neutral → Neutral | — | $187.38 | $191.27 | +2.1% | +3.7% | +3.4% | -0.8% | -0.7% | -1.6% |
| Jul 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $164.47 | $165.88 | +0.9% | -1.5% | +2.2% | -1.6% | -1.6% | -1.5% |
| May 19 | JP Morgan | Maintains | Overweight → Overweight | — | $142.82 | $140.09 | -1.9% | +0.5% | +1.0% | -5.3% | +0.5% | -0.8% |
| May 15 | Mizuho | Maintains | Outperform → Outperform | — | $141.82 | $140.83 | -0.7% | -1.0% | +1.7% | +0.5% | +1.0% | -5.3% |
| May 7 | UBS | Maintains | Buy → Buy | — | $146.20 | $149.60 | +2.3% | +4.9% | -0.0% | -2.8% | +4.8% | -3.5% |
| May 7 | Baird | Maintains | Neutral → Neutral | — | $146.20 | $149.60 | +2.3% | +4.9% | -0.0% | -2.8% | +4.8% | -3.5% |
| May 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $146.20 | $149.60 | +2.3% | +4.9% | -0.0% | -2.8% | +4.8% | -3.5% |
| May 7 | Citigroup | Maintains | Neutral → Neutral | — | $146.20 | $149.60 | +2.3% | +4.9% | -0.0% | -2.8% | +4.8% | -3.5% |
| Apr 25 | HSBC | Downgrade | Buy → Hold | — | $150.68 | $147.07 | -2.4% | -0.3% | -0.1% | +2.2% | +1.1% | -2.6% |
| Apr 10 | Barclays | Downgrade | Overweight → Equal Weight | — | $157.02 | $152.00 | -3.2% | -8.8% | +1.6% | +3.7% | -1.2% | -0.5% |
| Apr 10 | Truist | Maintains | Buy → Buy | — | $157.02 | $152.00 | -3.2% | -8.8% | +1.6% | +3.7% | -1.2% | -0.5% |
| Apr 9 | Mizuho | Maintains | Outperform → Outperform | — | $144.49 | $140.91 | -2.5% | +8.7% | -8.8% | +1.6% | +3.7% | -1.2% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $184.85 | $184.73 | -0.1% | -0.7% | +1.2% | -0.2% | +3.3% | -1.5% |
| Feb 18 | JP Morgan | Maintains | Overweight → Overweight | — | $193.44 | $193.09 | -0.2% | -0.1% | +1.7% | -1.3% | -1.5% | +1.9% |
| Feb 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $206.97 | $203.27 | -1.8% | -2.9% | -1.5% | -0.9% | -1.3% | -0.1% |
| Feb 10 | RBC Capital | Maintains | Outperform → Outperform | — | $208.14 | $209.63 | +0.7% | -0.6% | -2.9% | -1.5% | -0.9% | -1.3% |
| Feb 10 | Truist | Maintains | Buy → Buy | — | $208.14 | $209.63 | +0.7% | -0.6% | -2.9% | -1.5% | -0.9% | -1.3% |
| Feb 7 | Stifel | Maintains | Buy → Buy | — | $209.96 | $211.67 | +0.8% | -0.9% | -0.6% | -2.9% | -1.5% | -0.9% |
| Feb 7 | UBS | Maintains | Buy → Buy | — | $209.96 | $211.67 | +0.8% | -0.9% | -0.6% | -2.9% | -1.5% | -0.9% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $201.36 | $196.50 | -2.4% | -1.1% | +0.5% | +2.7% | +2.2% | -0.9% |
No insider trades available.
8-K · 2.02
!! High
IQVIA Holdings Inc. -- 8-K 2.02: Earnings Results
IQVIA Holdings reported Q1 2026 earnings results on May 5, 2026, with detailed financial performance metrics available in the accompanying press release exhibit.
May 5
8-K
IQVIA Holdings Inc. -- 8-K Filing
IQVIA's executive compensation plan allows the Compensation Committee to establish performance metrics and award share payouts within predetermined ranges based on achievement of corporate goals.
Apr 23
8-K · 7.01
! Medium
Charles River Laboratories International, Inc. -- 8-K 7.01: Regulation FD Disclosure
Charles River Laboratories plans to divest its CDMO and Cell Solutions businesses, eliminating revenue streams from advanced therapy manufacturing services and cellular materials, potentially impacting investor returns.
Feb 25
8-K · 5.02
!!! Very High
Baxter International Inc. -- 8-K 5.02: Executive Change
Baxter International appointed Michael R. McDonnell as Executive Vice President effective February 13, 2026, signaling internal leadership development and potential changes to executive responsibilities.
Feb 12
8-K
IQVIA Holdings Inc. -- 8-K Filing
IQVIA delivered strong fourth-quarter 2025 results across all business segments, demonstrating solid operational momentum for the healthcare intelligence and clinical research provider.
Feb 5
Data updated apr 25, 2026 4:10pm
· Source: massive.com